Novo Nordisk's GlucaGen Recombinant Glucagon Approved As Imaging Agent
This article was originally published in The Gray Sheet
Executive Summary
Novo Nordisk is delaying the launch of GlucaGen pending the finalization of a co-marketing agreement. The first recombinant DNA glucagon product to clear FDA, GlucaGen was approved June 22 as a diagnostic aid and for the treatment of severe hypoglycemia in diabetes patients.